Oddity Is Nursing a Private Wound While the Market Frets About Tariffs
IL MAKIAGE's ad-account dislocation cut revenue 25% — but the real bet is a medical-grade pivot into hyperpigmentation, peptides and longevity that the tape hasn't priced.
ODD · Earnings Call · 2026-09-09
The wound is company-specific, not cyclical
Oddity's Q2 was grim on the surface. Net revenue fell “25% versus the prior year to $181 million, at the favorable end of our guidance” — Lindsay Mann, Global CFO · 2026-09-09, with first orders down roughly 40%, repeat off ~20%, AOV −8% and gross margin slipping to 68.7% from 72.3%. The cause is a single, oddly technical phrase that dominates the company's own keyword cloud this quarter: the algorithm dislocation. Here is the tell — scan the global editor-curated top-75 lists for the last twelve quarters and that phrase appears nowhere. Every other big theme in ODD's call has a market echo; this one is a private wound. The closest global cousins are AI-risk software themes from 2026Q1, which are a different animal entirely. Contrast that with what the whole market is actually chewing on. net tariff refunds ranked third globally in 2026Q3, and no fewer than four companies that reported alongside Oddity — AEO, ASO, JILL and SIG — went out of their way to flag tariff refunds. Oddity's call is silent on the topic. On both axes, then, this is an idiosyncratic story: a D2C beauty brand dealing with a distribution-algorithm problem while the rest of the tape trades macro trade policy.What's genuinely new: a medical pivot dressed as damage control
Beneath the decline, the call quietly repositions Oddity. METHODIQ, the medical-grade brand, is now the narrative engine. The hero is hyperpigmentation — a computer-vision assessment feeding a personalized treatment plan, with the proprietary molecule combination Melanex 509 at the center. Note how the language shifts from cosmetics to clinics: management now leads with medical grade positioning and a mix of prescription product and OTC protocols. And then the genuinely forward statement: “One category we are particularly excited about for next year is longevity and metabolic health. As a first step, we plan to deliver legally available prescription injectable and peptide therapies” — Oran Holtzman, Co-founder and CEO · 2026-09-09. That is Oddity planting a flag in the same ground the market is already bidding up — the global 30-day advancer list carries oral GLP 1, and the "weight health" idea has been a persistent market theme. Oddity is arriving late to that wave, but arriving with a distribution machine.The recurring thing that still hasn't been fixed
Be careful not to let the shiny new categories bury the old problem. The advertising partner dislocation is now a three-quarter-plus saga, not a fresh shock. Back on the February call, Lindsay Drucker Mann warned that “at current CPAs, we are not profitable at first order” — Lindsay Mann, Global CFO · 2026-02-25, and that “we don't have a brand issue” — Lindsay Mann, Global CFO · 2026-02-25. By June, first orders had fallen ~50% and management was flagging the compounding “first orders were down, as I mentioned in my script, around 50%” — Lindsay Mann · 2026-06-02 — repeat revenue that never gets born. On this call, the diagnosis has barely moved: “it looks like there is an audience drift from the algorithm, and we are trying to retrain it” — Oran Holtzman, Co-founder and CEO · 2026-09-09. The improvement is real but forward-loaded. Guidance is for Q3 revenue to fall only ~5% year-over-year, but the full-year figure still implies roughly a low-teens decline in Q4 — and management is candid that it is holding back budget for testing: “we want to be conservative since we do not know yet how we want to allocate our spending budget” — Lindsay Mann, Global CFO · 2026-09-09. Translation: the visibility is thin.Full power, non-stop hard work until fixing the problem, no other way.